Case Study: a Fortune 500 pharmaceutical company reduces therapy discontinuation risk with Tiger Analytics' ML model

a Fortune 500 Pharmaceutical Company predicts therapy discontinuation for 7,000 patients with Tiger Analytics

A Fortune 500 pharmaceutical company sought to improve patient outcomes by understanding and preventing therapy discontinuation. They faced challenges in predicting which patients would stop treatment within six months, complicated by evolving data processes and intangible factors like patient perception. The company engaged Tiger Analytics, leveraging their data science and predictive modeling services.

Tiger Analytics processed diverse data sources to build a machine learning model that identified patients at risk. Analyzing a sample of 7,000 patients across two therapeutic areas, the solution provided root-cause insights into discontinuation. This enabled the client to design targeted care plans, successfully predicting therapy discontinuation and enhancing their ability to support patient adherence.